IMDX Earnings

IMDX reported its earnings on 2025-11-10, showcasing a revenue of 260.00K against an estimate of 285.00K, resulting in a -8.77% surprise. The EPS was -0.34, surpassing the expected -0.24 by -41.67%. The stock experienced a 10.66% price change on the earnings day and a 8.82% change over the next five days, reflecting market reactions to the results.

Following IMDX's earnings announcement on 2025-11-10, the stock price moved by 10.66% on the day of the release. Over the subsequent five days, it saw a 8.82% change. Historically, IMDX's stock price tends to shift by an average of 1.25% in the 10 days leading up to earnings and -7.33% in the 10 days following, providing insight into potential market.

For , analysts estimate IMDX's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between IMDX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IMDX's stock price typically moves by 1.25% in the 10 days before its earnings and -7.33% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call presents a mixed outlook. Financial performance and shareholder returns were not explicitly discussed, but R&D expenses are high, and there's uncertainty in EU reimbursement. Positive aspects include a large TAM, engagement with transplant centers, and promising registry study potential. The Q&A highlights active partnerships and strategic focus on heart transplants, but also notes high cash burn and regulatory challenges. Overall, the sentiment is neutral, with some positive growth indicators balanced by financial and regulatory uncertainties.